A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis.

Trial Profile

A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs AK 106-001616 (Primary) ; Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Asahi Kasei
  • Most Recent Events

    • 16 Nov 2011 Actual initiation date changed from 1 May 2009 to 24 Mar 2009 and official title amended as reported by European Clinical Trials Database.
    • 08 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top